Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.
Carlo Salvarani,Marco Massari,Massimo Costantini,Domenico Franco Merlo, Gabriella Lucia Mariani,Pierluigi Viale,Stefano Nava,Giovanni Guaraldi,Giovanni Dolci,Luca Boni,Luisa Savoldi,Paolo Bruzzi,Caterina Turrà,Mariagrazia Catanoso,Anna Maria Marata,Chiara Barbieri,Annamaria Valcavi,Francesca Franzoni,Silvio Cavuto,Giorgio Mazzi,Romina Corsini,Fabio Trapani,Alessandro Bartoloni,Emanuela Barisione,Chiara Barbieri,Giulia Jole Burastero,Angelo Pan, Walter Inojosa,Raffaele Scala, Cecilia Burattini,Fabrizio Luppi,Mauro Codeluppi, Kamal Eldin Tarek,Giovanni Cenderello,Mario Salio,Giuseppe Foti, Roberto Dongilli, Gianluigi Bajocchi,Emanuele Alberto Negri,Giacomo Ciusa,Giacomo Fornaro, Ilaria Bassi,Lorenzo Zammarchi,Teresita Aloè,Nicola Facciolongo The European respiratory journal（2022）
摘要
Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia.
更多查看译文
关键词
intravenous methylprednisolone pulses,pneumonia,patients,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
